Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study (CHD-PAHCS)

Wuhan Asia Heart Hospital

Status

Unknown

Conditions

Pulmonary Arterial Hypertension

Treatments

Other: standard of care

Study type

Observational

Funder types

Other

Identifiers

NCT03977428

2019LMC-1

Details and patient eligibility

About

The study will recruit and follow up patients for five years patients newly diagnosed with congenital heart disease associated pulmonary arterial hypertension(CHD-PAH) from the investigator's hospital. The main aim of the study is to describe the aetiology, natural history and management practices of CHD-PAH in central China.

Full description

baseline include: An echocardiogram to assess the size, shape, pumping action and the extent of any damage to the heart.

Lung function tests which include blowing measurements to assess gas volumes within the lungs as well as assessment of how the lungs exchange gases.

Right heart catheterisation (RHC) to diagnose PAH Optional Cardiac Magnetic Resonance tests. 6 minute walk distance (6MWD). To measure exercise capacity Electrocardiogram (ECG), a test that measures the electrical activity of the heart Blood tests

main outcome measure include:

death heart/lung transplantation atrial septostomy hospitalization due to worsening of PAH start of new specific PAH treatment persistent decrease of >15% from baseline in 6MWD (or >30% compared with last study-related measurement) persistent worsening of World Health Organization (WHO) Functional Class (FC）

Enrollment

500 estimated patients

Sex

All

Ages

1 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

-Clinical diagnosis of CHD-PAH (by RHC)

Exclusion criteria